The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.